Filtered By:
Source: Vaccine
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 465 results found since Jan 2013.
Antibodies against Neisseria meningitidis serogroups A, C, W and Y in serum and saliva of Norwegian adolescents
CONCLUSION: Unvaccinated adolescents in Norway have a low degree of natural immunity against the serogroups of N. meningitidis predominating among cases of IMD in this age group. Therefore, introduction of MCV4 for adolescents in the NIP is recommended.PMID:37648606 | DOI:10.1016/j.vaccine.2023.08.052
Source: Vaccine - August 30, 2023 Category: Allergy & Immunology Authors: Sara Viksmoen Watle Bente B ørud Ida Laake Marta Baranowska-Hustad Diane Bryant-Bratlie Terese Bekkevold Dominique A Caugant Gro Tunheim Lisbeth Meyer N æss Source Type: research
Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" Vaccine 41(1) (2023) 85-91
Vaccine. 2023 Aug 23:S0264-410X(23)00870-8. doi: 10.1016/j.vaccine.2023.07.039. Online ahead of print.NO ABSTRACTPMID:37625991 | DOI:10.1016/j.vaccine.2023.07.039
Source: Vaccine - August 25, 2023 Category: Allergy & Immunology Authors: Nusrat Homaira Roxanne Strachan Helen Quinn Sean Beggs Mejbah Bhuiyan Asha Bowen Laura K Fawcett Gwendolyn L Gilbert Stephen B Lambert Kristine Macartney Helen S Marshall Andrew C Martin Gabrielle McCallum Angela McCullagh Tim McDonald Hiran Selvadurai Pe Source Type: research
Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study
CONCLUSIONS: PCV13 vaccination among children aged 0-5 years substantially reduced the incidence of all-cause pneumonia. Direct immunization of children under 5 years is an effective strategy to combat outpatient pneumonia, and hospitalized pneumonia.PMID:37620204 | DOI:10.1016/j.vaccine.2023.08.041
Source: Vaccine - August 24, 2023 Category: Allergy & Immunology Authors: Jie Tian Bo Zheng Laibao Yang Ying Guan Chunze Xu Weibing Wang Source Type: research
Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies
CONCLUSIONS: Vaccinating older adults with higher-valency PCVs, especially PCV20, could substantially reduce the remaining IPD burden in high-income countries, regardless of current PCV use in pediatric NIPs and adult PPSV23 policies.PMID:37544825 | DOI:10.1016/j.vaccine.2023.08.001
Source: Vaccine - August 6, 2023 Category: Allergy & Immunology Authors: Lindsay R Grant Mary P E Slack Christian Theilacker Jelena Vojicic St éphane Dion Ralf-Rene Reinert Luis Jodar Bradford D Gessner Source Type: research
Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines
Vaccine. 2023 Jul 30:S0264-410X(23)00885-X. doi: 10.1016/j.vaccine.2023.07.054. Online ahead of print.ABSTRACTFor the batch release of vaccines, potency release assays are required. Non-animal in vitro tests have numerous advantages and are preferred; however, several vaccines are still released using in vivo assays. Their major drawback is the inherent variability with its practical implications. We quantified the variability of in vivo potency release assays for whole-cell pertussis, inactivated polio and meningococcal B (MenB) vaccines which showed large CV (Coefficient of Variation) ranging from 34% to 125%. As inheren...
Source: Vaccine - August 1, 2023 Category: Allergy & Immunology Authors: Cerissa van Walstijn Stefan Verweij Rory Care Peter Rigsby Eli-Boaz Clapper Kevin Markey Rob J Vandebriel Paul Stickings Marcel H N Hoefnagel Source Type: research
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.PMID:37507273 | DOI:10.1016/j.vaccine.2023.07.042
Source: Vaccine - July 28, 2023 Category: Allergy & Immunology Authors: Alamgir Kabir Deborah Randall Anthony T Newall Hannah C Moore Sanjay Jayasinghe Parveen Fathima Bette Liu Peter McIntyre Heather F Gidding Source Type: research
Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial
CONCLUSION: Even after PCV10 or PCV13 vaccination, children living in a high-risk setting such as PNG continue to experience high levels of pneumococcal colonization, including carriage of highly antimicrobial-resistant PCV serotypes. The study is registered with ClinicalTrials.gov (CTN NCT01619462).PMID:37479616 | DOI:10.1016/j.vaccine.2023.07.026
Source: Vaccine - July 21, 2023 Category: Allergy & Immunology Authors: Tilda Orami Celestine Aho Rebecca L Ford William S Pomat Andrew Greenhill Lea-Ann Kirkham Geraldine Masiria Birunu Nivio Kathryn J Britton Peter Jacoby Peter C Richmond Anita H J van den Biggelaar Deborah Lehmann Source Type: research
Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain
CONCLUSIONS/RECOMMENDATIONS: In the Spanish adult population older than 60 years, the vaccination strategy with one dose of PCV20 is more effective and less expensive (dominant) than vaccination with a sequential schedule with PCV15 and PPSV23.PMID:37479615 | DOI:10.1016/j.vaccine.2023.07.016
Source: Vaccine - July 21, 2023 Category: Allergy & Immunology Authors: David Cantarero Daniel Oca ña Mar ía Ángeles Onieva-García Juan Rodr íguez-García Paulina G álvez Cristina M éndez Carlos Crespo Alejandra L ópez-Ibáñez de Aldecoa Source Type: research
